Transforming growth factor-b (TGF-b) is overexpressed at sites of wound repair and in most adenocarcinomas including prostate cancer. In stromal tissues, TGF-b regulates cell proliferation, phenotype and matrix synthesis. To address mechanisms of TGF-b action in cancerassociated reactive stroma, we developed prostate stromal cells null for TGF-b receptor II (TbRII) or engineered to express a dominant-negative Smad3 to attenuate TGF-b signaling. The differential reactive stroma (DRS) xenograft model was used to evaluate altered stromal TGF-b signaling on LNCaP tumor progression. LNCaP xenograft tumors constructed with TbRII null or dominantnegative Smad3 stromal cells exhibited a significant reduction in mass and microvessel density relative to controls. Additionally, decreased cellular fibroblast growth factor-2 (FGF-2) immunostaining was associated with attenuated TGF-b signaling in stroma. In vitro, TGF-b stimulated stromal FGF-2 expression and release. However, stromal cells with attenuated TGF-b signaling were refractory to TGF-b-stimulated FGF-2 expression and release. Re-expression of FGF-2 in these stromal cells in DRS xenografts resulted in restored tumor mass and microvessel density. In summary, these data show that TGF-b signaling in reactive stroma is angiogenic and tumor promoting and that this effect is mediated in part through a TbRII/Smad3-dependent upregulation of FGF-2 expression and release.
Introduction
Several studies suggest that a reactive stroma microenvironment affects rate of carcinoma progression, although key factors and signaling mechanisms are poorly understood. Transforming growth factor-b (TGF-b) is overexpressed in most carcinomas and regulates diverse functions of stromal cells through both Smad-dependent and -independent signaling pathways (Coffey et al., 1986; Roberts et al., 1986; Roberts and Sporn, 1996; Derynck and Zhang, 2003) . TGF-b modulates stromal cell phenotype, promotes matrix remodeling, promotes angiogenesis and affects immune responses at sites of tumor formation (Rowley, 2007) . Most of these actions are considered tumor promoting. TGF-b has also been considered a tumor suppressor, as it inhibits proliferation of normal epithelial cells; however, many carcinoma cells become refractory to the growth inhibitory activity of TGF-b due to loss or mutation of various TGF-b signaling pathway components in these cells during tumorigenesis (Akhurst and Derynck, 2001) . Therefore, understanding the net effects of TGF-b in carcinoma progression is complicated. Net response to TGF-b is likely to be dynamic during evolution of a tumor and will reflect the combined effects of this factor on both carcinoma cells and on all components of the reactive stroma microenvironment.
We have previously shown that a reactive stroma co-evolves early in human prostate cancer during the formation of pre-malignant prostatic intraepithelial neoplasia (PIN) (Tuxhorn et al., 2002a) . This reactive stroma was typified by carcinoma-associated fibroblasts, myofibroblasts and matrix remodelling. Elevated TGFb expression was observed in PIN epithelia and prostate cancer cells. We also showed that TGF-b could induce human prostate fibroblasts to a myofibroblast phenotype in vitro with elevated expression of tenascin, a marker of reactive stroma (Tuxhorn et al., 2002a) . Our previous studies have developed a xenograft model (differential reactive stroma, DRS) that recombines LNCaP prostate carcinoma cells with engineered prostate stromal cells (Tuxhorn et al., 2002b, c; Yang et al., 2005) . In these studies we have shown that reactive stroma promotes experimental prostate cancer progression and much of this was due to stromal regulation of angiogenesis (Tuxhorn et al., 2002b) . Using this same experimental xenograft model, we have also reported that both TGF-b and connective tissue growth factor (CTGF), a downstream mediator of TGF-b action, stimulate angiogenesis and promote tumorigenesis (Tuxhorn et al., 2002c; Yang et al., 2005) . In contrast, under different conditions with different models and carcinoma/stromal cell lines, other studies showed that loss of TGF-b signaling in stroma resulted in elevated expression of tumor-promoting factors (TGF-a and HGF) and a net tumor progression (Bhowmick et al., 2004; Cheng et al., 2005) . Together, these studies support the concept that the actions of TGF-b and specific signaling pathways, including downstream mediators expressed in reactive stroma, is an important area for further study. In addition, although the role of Smad3-mediated TGF-b signaling in tissue fibrosis or wounding has been studied (Roberts et al., 2003; Lakos et al., 2004) , it is not known whether Smad3 mediates TGF-b induction of angiogenesis and reactive stroma during carcinoma progression. Accordingly, in order to more clearly define the complicated regulation of carcinogenesis by TGF-b action in stroma, the purposes of this study were to determine whether Smad3-mediated TGF-b signaling is a key pathway in cancerassociated stroma and to subsequently assess candidate downstream mediators of TGF-b/Smad3 biological action.
In this report, we use the LNCaP carcinoma/prostate stromal cell recombined DRS xenograft model to show that loss of TGF-b signaling in prostate stromal cells through either a targeted knockout of TGF-b receptor II (TbRII) or by expression of a dominant-negative Smad3 results in an inhibition of the angiogenesis-and tumor-promoting function of reactive stroma. In addition, we show that the angiogenic and tumorigenic function of stromal TGF-b signaling is mediated, in part, by induced expression and release of FGF-2 from prostate stromal cells in a TbRII/Smad3-dependent manner.
Results
Attenuated TGF-b response in prostate stromal cells The TbRII flox/flox H, TbRII KO, TbRII CT, Smad3 Ctrl and Smad3 DN prostate stromal cell lines were generated as described in Materials and methods. Table 1 summarizes the designated name for each prostate stromal cell line and how each cell line was derived and/or engineered. In TbRII flox/flox H and TbRII CT control cells, TGF-b1 (50 pM) stimulated a seven-to eight-fold expression of p800Luc (PAI-1 promoter), a three-fold expression of a-SMAp-luc (smooth muscle a-actin promoter) and a three-to four-fold expression of pVim-luc (vimentin promoter) (Figure 1a ). In contrast, there was no significant TGF-b1-induced promoter activity with any of these constructs in the TbRII KO cells. TGF-b1 also induced a 250-to 270-fold expression of (CAGA) 12 MLP (Smad binding sequence) in control cell lines, whereas this induction was restricted to 2.6-fold in TbRII KO cells (Figure 1a ). Our previous study showed that TGF-b1 induces a myofibroblast/smooth muscle phenotype in prostate stromal cells in vitro (Tuxhorn et al., 2002a) . Concordantly, TGF-b1 induced smooth muscle a-actin filament formation in TbRII CT control cells; however, TbRII KO cells were refractory to TGF-b-induced filament formation (Figure 1b) . Attenuated stromal TGF-b signaling in LNCaP þ stroma xenografts Construction of LNCaP/prostate stromal cell xenografts and evaluation time points followed protocols identical to what we have published previously (Tuxhorn et al., 2002b, c; Yang et al., 2005) . Xenografts that were constructed with LNCaP plus TbRII KO stromal cells resulted in a 44.1% decrease in microvessel density (Po0.0001, n ¼ 72 fields from 12 xenografts in each group) and a 49.8% decrease in tumor mass compared to LNCaP plus TbRII CT control stromal cells ( Figure 3a) (Figures 7a and b) with subsequent experiments, Figure 7 shows histology for all xenografts in this study. To confirm the histological observations, carcinoma cell to stromal cell ratios were determined in xenografts as described in Materials and methods. No statistically significant differences were observed in carcinoma cell to stromal cell ratios between experimental and control xenografts within each data set (data not shown).
Similar decreases in mass and microvessel density were observed in LNCaP plus Smad3 DN xenografts Figure 3a .
b Tumor data compared in Figure 3b .
c Tumor data compared in Figure 6c . d Tumor data compared in Figure 6d .
TGF-b signaling in prostate cancer reactive stroma F Yang et al evaluated at both 2-week (day 14) and 4-week (day 28) end points. LNCaP/Smad3 DN xenografts exhibited a 24.5% decrease in mean mass at 2 weeks compared to control LNCaP/Smad3 Ctrl xenografts (P ¼ 0.0014, n ¼ 18) (data not shown). At the 4-week end point, a 31.4% decrease in microvessel density (P ¼ 0.0089, n ¼ 72 fields/12 xenografts) and a 40.6% decrease in mean wet weight (P ¼ 0.0216, n ¼ 18) was observed in LNCaP/Smad3 DN xenografts relative to LNCaP/Smad3 Ctrl xenografts ( Figure 3b ). As discussed above, no differences in histology or carcinoma cell to stromal cell ratios were observed (Figures 7d and e) .
TGF-b1 induces FGF-2 mRNA and protein expression in stromal cells Stromal cells were examined by quantitative realtime PCR (qPCR) to assess whether TGF-b1 stimulated FGF-2 mRNA expression. TGF-b1 stimulated expression of FGF-2 mRNA by 2-to 7-fold in both the TbRII CT (P ¼ 0.0332) and Smad3 Ctrl control (P ¼ 0.0133) prostate stromal cells (Figure 4a ). In contrast, FGF-2 mRNA remained at basal levels and was refractory to TGF-b1 stimulation in both the TbRII KO and Smad3 DN prostate stromal cells. Consistent with this observation, stromal FGF-2 immunoreactivity was greatly decreased in LNCaP/TbRII KO xenografts 
TGF-b1 induces FGF-2 release in stromal cells
Extracts from stromal cells stimulated with TGF-b1 showed that total cellular FGF-2 protein was significantly elevated in both TbRII CT and Smad3 Ctrl cells as determined by enzyme-linked immunosorbent assay (ELISA) (P ¼ 0.0166 and Po0.0001, respectively; Figure 5a ). This effect was abrogated in TbRII KO and Smad3 DN cells. Detection of FGF-2 released into conditioned media by control cells was below the ELISA detection threshold. Hence, to determine whether TGFb1 also induces FGF-2 protein secretion/release, TbRII CT, TbRII KO, Smad3 Ctrl and Smad3 DN prostate stromal cells were each engineered to overexpress an 18 kDa FGF-2-GFP (green fluorescent protein) fusion protein. Under these conditions, TGF-b1 induced a significant, dose-dependent secretion/release of FGF-2 protein into the conditioned media in both the control TbRII CT þ FGF-2 (P ¼ 0.0472) and the Smad3 Ctrl þ FGF-2 cells (P ¼ 0.0085) (Figure 5b ). Conversely, TGF-b1 had no effect on FGF-2 release from the TbRII KO þ FGF-2 or Smad3 DN þ FGF-2 cells. As a control, western blot results show that ectopic FGF-2 was expressed at equivalent levels in control cells and cells with attenuated TGF-b signaling (Figure 5b , inset).
TbRII/Smad3-mediated FGF-2 expression in prostate stromal cells promotes angiogenesis and xenograft tumor growth To determine whether the tumor-inhibiting effects of attenuated TGF-b signaling in stromal cells could be attributed to decreased FGF-2 expression, xenografts were constructed with LNCaP cells plus either TbRII KO or Smad3 DN cells engineered to overexpress the 18 kDa FGF-2-GFP fusion protein (TbRII KO þ FGF-2 and Smad3 DN þ FGF-2, respectively) or the empty vector control (TbRII KO þ Ctrl or Smad3 DN þ Ctrl) as described above. LNCaP/TbRII KO þ FGF2 xenografts exhibited a recovery of stromal FGF-2 immunostaining ( Figure 6a ) and this was due to the expression of the FGF-2-GFP fusion protein as these cells were also positive for GFP (Figure 6b ). Overexpression of FGF-2 under these conditions produced a 40.0% increase in xenograft mass in LNCaP/TbRII KO þ FGF2 xenografts compared to LNCaP/TbRII KO þ Ctrl xenografts at the 2-week end point (P ¼ 0.0127, n ¼ 18) (data not shown). This expanded to a 141.1% increase in xenograft mass in LNCaP/TbRII KO þ (Figure 6c) . Similarly, overexpression of FGF-2 in Smad3 DN stromal cells produced a 30.4% increase in LNCaP/Smad3 DN þ FGF-2 xenograft mass compared to LNCaP/Smad3 DN þ Ctrl control xenografts at the 2-week end point (P ¼ 0.0138, n ¼ 18; Figure 6d ). Interestingly, the mean mass in LNCaP/Smad3 DN þ FGF-2 xenografts (24.1571.76 mg) is comparable to the mean mass of 2-week control LNCaP/Smad3 Ctrl xenografts (28.4671.21 mg) with intact Smad3 signaling. Furthermore, LNCaP/Smad3 DN þ FGF-2 xenografts showed a 45.3% increase in microvessel density compared to control LNCaP/Smad3 DN þ Ctrl xenografts (P ¼ 0.0027, n ¼ 72 fields/12 xenografts; Figure 6d ). Histopathologic analysis showed that there were no obvious differences in histology between control xenografts and xenografts with attenuated TGF-b signaling or xenografts with attenuated TGF-b signaling and overexpression of FGF-2 ( Figure 7) . As in previous experiments, there were no statistically significant differences in carcinoma to stromal cell ratios in these experiments (data not shown).
Discussion
Data presented here represent the first direct experimental evidence that links TGF-b signaling in the stromal compartment with the angiogenic, tumorpromoting effects of reactive stroma in an experimental human prostate cancer model. These data show that tumor-promoting TGF-b signaling in prostate stromal cells is mediated through a Smad3 pathway, although our results do not rule out other TGF-b-activated signaling pathways. In addition, these data show that the biological action of TGF-b signaling in reactive stroma is mediated, in part, through stimulated expression and secretion/release of FGF-2, also in a Smad3-regulated manner. Coordinate TGF-b/FGF-2 signaling in stroma resulted in elevated vessel density and prostate cancer xenograft growth, consistent with pro-reactive stroma and pro-angiogenic activities of both TGF-b1 (Roberts et al., 1986) and FGF-2 (Dow and deVere White, 2000) . These results suggest that TGF-b1 is a key upstream factor that regulates stromal microenvironment biology during prostate cancer progression and that signaling through Smad3 is a critical pathway. Data TGF-b signaling in prostate cancer reactive stroma F Yang et al presented here are consistent with the implication of Smad3 in mediating wound healing and fibrosis. As might be predicted, Smad3 null mice were refractory to TGF-b1-induced pulmonary fibrosis (Bonniaud et al., 2004) . However, the function of Smad3 in mediating TGF-b-induced responses in cancer-associated reactive stroma biology is poorly understood. Data here suggest that Smad3-mediated pathways may be common to tissue wound repair, fibrosis and reactive stroma in cancer.
Our previous reports have shown that TGF-b is overexpressed in pre-malignant PIN epithelia and that a reactive stroma phenotype co-evolved at sites adjacent to PIN (Tuxhorn et al., 2002a) . This initial reactive stroma consisted of carcinoma-associated fibroblasts, myofibroblasts and matrix remodeling, typical of a wound repair stroma. Matrix remodeling was typified by overexpression of collagen I, tenascin and fibroblast activation protein. TGF-b1 stimulates synthesis of matrix components by fibroblasts, including collagen type I and promotes angiogenesis in wound repair granulation tissue (Roberts et al., 1986; Roberts and Sporn, 1996) . In prostate stromal cells, TGF-b1 induced synthesis of collagen type I (Fukabori et al., 1997) , fibronectin (Butter et al., 2001) , tenascin (Tuxhorn et al., 2002c) , versican (Sakko et al., 2001 ) and induced myodifferentiation (Peehl and Sellers, 1998; Tuxhorn et al., 2002a) . TGF-b1 is overexpressed in many carcinomas, including prostate cancer epithelial cells (Eastham et al., 1995) , and has been reported as a primary inducer of myofibroblast differentiation in reactive stroma fibroblasts (Desmouliere et al., 1993; TGF-b signaling in prostate cancer reactive stroma F Yang et al Tuxhorn et al., 2002a) . Consistent with this, the myofibroblast is a common stromal cell type in carcinoma-associated stroma in many different epithelial cancers (Ronnov-Jessen et al., 1996; Tuxhorn et al., 2002a) . The carcinoma-associated reactive stroma in human cancer has been characterized as being similar to a wound repair granulation tissue, which commonly has a high myofibroblast population (Dvorak, 1986; RonnovJessen et al., 1996; Rowley, 2007) . In granulation tissue, elevated angiogenesis is coordinate with elevated FGF-2 and it is well established that TGF-b promotes granulation tissue formation and angiogenesis (Roberts et al., 1986) . FGF-2 is TGF-b-regulated and a mitogen for epithelial and stromal cells while also playing a role in the migration of endothelial cells during blood vessel formation (Dow and deVere White, 2000) . Overexpression of FGF-2 in stromal cells is nearly universal in wound repair, fibroses and cancer-associated reactive stroma (Rowley, 2007) . In addition to its fibrogenic role during wound repair, a significant upregulation of FGF-2 is seen in a variety of cancers including prostate cancer (Giri et al., 1999; Dow and deVere White, 2000) . Concordantly, tumor growth in the TRAMP mouse prostate cancer model was slowed in an FGF-2 knockout background (Polnaszek et al., 2003) . In addition, FGF receptor 1 (FGFR1), a cognate receptor for FGF-2, is upregulated in epithelia during prostate cancer progression in human cancer (Giri et al., 1999) and in mouse prostate cancer models (Huss et al., 2003) . Elevated FGF-2 expression in the stroma might be expected to provide a growth advantage for carcinoma cells with elevated expression of FGFR1. Therefore, it is likely that a TGF-b1-regulated and Smad3-mediated expression and release of FGF-2 in reactive stroma provides a pro-angiogenic and pro-tumorigenic microenvironment. Accordingly, the TGF-b/FGF-2 signaling axis is likely to be a key regulatory component of carcinoma cell-stromal cell interaction.
Our results do not rule out the involvement of other TGF-b-regulated growth factors. We believe that it is highly unlikely that FGF-2 is the only pathway downstream of TGF-b in stroma promoting LNCaP tumor growth, but that it does partially mediate the angiogenic action of TGF-b. In addition to FGF-2, TGF-b stimulates expression of many other growth factors in stromal cells including vascular endothelial growth factor, heparin-binding-epidermal growth factor, interleukin-6 TGF-b signaling in prostate cancer reactive stroma F Yang et al and CTGF (Igarashi et al., 1993; Pertovaara et al., 1994; Story et al., 1996; Uchiyama-Tanaka et al., 2002; Hayashi et al., 2004; Yang et al., 2005) , some of which, similar to FGF2, are Smad3 regulated. Hence, focal overexpression of TGF-b at sites of early cancer might be expected to initiate a local reactive stroma, typified by matrix remodeling, induction of myofibroblasts, collagen deposition and induced angiogenesis, similar to the initiation of these events at sites of wound repair, where platelets release TGF-b. It is also becoming more clear that the net response to elevated TGF-b in cancer is likely to be mediated through a diverse set of downstream factors. Accordingly, the biology induced in the tumor microenvironment may be either tumor-promoting or tumor-inhibiting depending on many local variables. Regardless, co-evolution of a reactive stroma does seem to correlate with tumor progression. Hence, it has been suggested by several that stimulation of a local host reactive microenvironment is a key step during transition of pre-neoplastic foci to overt neoplasia (Ronnov-Jessen et al., 1996; Liotta and Kohn, 2001; Tuxhorn et al., 2001) . In this study, we propose that the TGF-b/FGF-2 signaling axis is likely to be one of many coordinate sets of factors that regulate the complex biology of a reactive stroma microenvironment in carcinomas.
Materials and methods

Cell lines
LNCaP and Phoenix E cells were purchased from ATCC (Manassas, VA, USA) and maintained as described previously (Yang et al., 2005) . The C57B mouse prostate stromal cell line was generated and cultured as reported previously (Yang et al., 2005) . A prostate stromal cell line was initiated from the ventral prostate of an 8-week Tgfbr2 floxE2/floxE2 mouse (Bhowmick et al., 2004) carrying loxP sites at introns 1 and 2 of the TbRII gene, following the same procedure as reported previously (Yang et al., 2005) (Silver and Livingston, 2001) were transfected into Phoenix E cells with a Calcium Phosphate Transfection kit (Invitrogen, Carlsbad, CA, USA). Virus was collected, filtered (0.45 mm) and applied to infect TbRII flox/flox H cells as described previously (Yang et al., 2005) . Cre-GFP expression in TbRII flox/flox H cells excised the floxed TbRII alleles and self-excised the lox 511 flanked Cre-GFP (thus 'Hit and Run'), resulting in TbRII null cells named TbRII KO. CreY324F-GFP did not excise TbRII alleles and the resulting cells were named TbRII CT.
N-Flag-Smad3DSSVS expression in C57B prostate stromal cells To inhibit Smad3-mediated signaling, either pLPCX-N-FlagSmad3DSSVS or control pLPCX (Choy et al., 2000) was transfected into Phoenix E cells. Virus was collected, filtered and applied to infect C57B prostate stromal cells. Cells were selected with 2 mg/ml puromycin. The resulting cell lines were named Smad3 DN and Smad3 Ctrl.
Overexpression of FGF-2 FGF-2-GFP cDNA encoding an 18 kDa isoform FGF-2 fused to GFP protein was subcloned from pRev-TRE2 (Backhaus et al., 2004) into pBMN-LacZ. Functionality of this protein has been described previously (Backhaus et al., 2004) . pBMN-FGF-2-GFP or pBMN-I-eGFP control vector was transfected into Phoenix E cells. Virus was collected, filtered and applied to infect TbRII KO or Smad3 DN cells. The resulting cell lines were named TbRII KO þ FGF-2, TbRII KO þ Ctrl, Smad3 DN þ FGF2 and Smad3 DN þ Ctrl. Methods for promoter assays, immunocytochemistry, quantitative PCR, ELISA and western blots using cell lines are provided in the Supplementary Information.
Animals and DRS xenografts
Athymic NCr-nu/nu male mice, 6-8 weeks of age, were purchased from Charles River Laboratories (Wilmington, MA, USA). All experiments were in compliance with the NIH Guide for the Care and Use of Laboratory Animals according to institutional guidelines of Baylor College of Medicine.
DRS xenografts were generated following procedures published previously (Tuxhorn et al., 2002b, c; Yang et al., 2005) . Briefly, 2 Â 10 6 LNCaP cells with 5 Â 10 5 of either TbRII CT, TbRII KO, Smad Ctrl, Smad3 DN, TbRII KO þ Ctrl, TbRII KO þ FGF2, Smad3 DN þ Ctrl or Smad3 DN þ FGF2 cells in matrigel were injected subcutaneously in each rear lateral flank of three mice for a total of six tumors per experimental group per injection preparation. A minimum of three independent experiments was performed for each combination tested (n ¼ 18 tumors). Xenograft tumors were evaluated at either day 14 or 28 after inoculation, as these are optimal intermediate and later stage time points as reported previously (Tuxhorn et al., 2002b, c; Yang et al., 2005) . Xenografts were weighed and fixed in 4% paraformaldehyde at 41C overnight and paraffin embedded. Sections (5 mm) were mounted onto ProbeOn Plus slides (Fisher, Pittsburgh, PA, USA) and either stained with H&E or processed for immunohistochemistry. Methods for immunohistochemistry, microvessel density counts and determination of carcinoma to stromal cell ratios are included in the Supplementary Information.
